1. Home
  2. HOFT vs MOLN Comparison

HOFT vs MOLN Comparison

Compare HOFT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hooker Furnishings Corporation

HOFT

Hooker Furnishings Corporation

N/A

Current Price

$13.00

Market Cap

144.6M

ML Signal

N/A

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.82

Market Cap

158.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HOFT
MOLN
Founded
1924
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
144.6M
158.9M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
HOFT
MOLN
Price
$13.00
$4.82
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
24.2K
1.8K
Earning Date
03-23-2026
01-01-0001
Dividend Yield
3.54%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$397,465,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.61
$285.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.34
$3.36
52 Week High
$15.99
$5.36

Technical Indicators

Market Signals
Indicator
HOFT
MOLN
Relative Strength Index (RSI) 36.13 53.05
Support Level $9.02 $3.50
Resistance Level $13.47 $5.36
Average True Range (ATR) 0.69 0.18
MACD -0.24 -0.03
Stochastic Oscillator 14.08 25.34

Price Performance

Historical Comparison
HOFT
MOLN

About HOFT Hooker Furnishings Corporation

Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: